key: cord-0692869-w1bbbav7 authors: Gonçalves, Carlos‐Alberto; Sesterheim, Patrícia title: Serum Amyloid A protein has been undervalued as a biomarker in cases of COVID‐19 date: 2020-06-26 journal: Diabetes Metab Res Rev DOI: 10.1002/dmrr.3376 sha: b90aeb4d4102be83a116cf83498f4269529f2310 doc_id: 692869 cord_uid: w1bbbav7 nan Hepatocytes respond to circulating cytokines (mainly IL-6) by synthesizing and secreting specific proteins, described as acute-phase proteins (APP). C-reactive protein (CRP) is the prototype of these proteins and increases in inflammatory states, whether infectious or not. 5 However, this innate immune system protein is not very useful in differentiating bacterial from viral infections. Supporting a hyperinflammation scenario, mediated by IL-6, a meta-analysis highlighted a reduced lymphocyte / CRP ratio as a marker of severity in COVID19. 6 Ferritin is another APP, and is frequently used as clinical marker, particularly in very used and very appropriate for cases of viral infections, 7 including COVID-19. In fact, Guo and co-workers found elevated levels of serum ferritin in COVID-17, but no difference was found between diabetic and non-diabetic Sar-Cov-2 infected patients (p = 0.15, Table 2 ). However, when other comorbidities (such as hypertension and pulmonary disease) were excluded, both the CRP and ferritin markers were observed as significantly elevated (p < 0.01, Table 4 ) in the diabetic patients, compared to non-diabetic ones. Nevertheless, we want, herein, to call attention to another APP, serum amyloid A (SAA). SAA, like CRP, is increased in chronic inflammatory processes, such as diabetes and obesity. A meta-analysis study indicated a strong correlation between elevated SAA and obesity, a major risk for diabetes mellitus type 2. 8 SAA is a pentraxin that activates the classic complement system via C1q and reinforces the production of the primary cytokines, IL-β1 and TNF, contributing to the cytokine storm. Interestingly, other important actions have been described for this protein; SAA is able to induce an atypical coagulation, which is dependent on fibrinogen, and mediate red blood cell (RBC) agglutination. 9 Moreover, when SAA is elevated it is found in apoB-containing lipoproteins (LDL and HDL), potentially favoring vascular atherogenesis. 10, 11 It may be hypothesized that an acute increase in SAA (compared to the already high levels found in diabetics) occurs in COVID-19 (see Figure 1 ). This could contribute to the severity of the clinical condition by leading to coagulopathy (not always accompanied by a large increase in fibrinogen, another APP), a reduction in pulmonary and tissue gas exchange (due to RBC agglutination) and atherogenesis (accentuating cardiovascular dysfunction). Although SAA may be more useful than CRP as a marker of viral infections, 12 data on SAA have not been reported in COVID-19. In a very recent paper, also from the Wuhan dataset, authors suggested SAA as a severity marker for COVID-19. 13 However, there is no information available on comorbidities in these critically ill patients. Guo and colleagues' data on the severity of COVID-19 in diabetic patients are very clear. 1 This commentary is to point out the need to investigate levels of SAA, particularly in obese and diabetic patients. This protein may play a key role in the pathogenesis of COVID-19, in addition to having a potential prognostic role. It would be of importance to include SAA measurement in ongoing protocols and further reports. induces the synthesis and release of acute-phase proteins (APP) in hepatocytes. Serum amyloid A (SAA), which is already elevated in chronic inflammatory conditions (e.g. obesity and diabetes mellitus), is one of the APP generated. This APP reinforces primary cytokine production, contributing to a cytokine storm. SAA directly binds to fibrinogen leading to an atypical coagulopathy. Moreover, it binds to apoB-containing lipoproteins, leading to HDL dysfunction, and induces red blood cell (RBC) agglutination. Taken together, these changes contribute to embolic and multiinfarct events in COVID-19. 140x134mm (96 x 96 DPI) This article is protected by copyright. All rights reserved. Diabetes is a risk factor for the progression and prognosis of COVID COVID-19 and diabetes: Knowledge in progress Cytokine release syndrome in severe COVID-19 On the alert for cytokine storm: Immunopathology in COVID-19 C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systemic review and meta-analysis Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections Association between serum amyloid A and obesity: a meta-analysis and systematic review Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation Serum amyloid A impairs the antiinflammatory properties of HDL Serum Amyloid A Is an Exchangeable Apolipoprotein Acute phase reactant serum amyloid A in inflammation and other diseases Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis The authors gratefully acknowledge to public funding agencies in Brazil: National Council for Scientific and Technological Development (CNPq), Coordination for the Improvement of Higher Education Personnel (CAPES), Research Support Foundation of Rio Grande do Sul (FAPERGS) and National Institute of Science and Technology for Excitotoxicity and Neuroprotection (INCTEN). The authors declare that they do not have any conflict of interest regarding this publication.